We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NAAG peptidase inhibitors and their potential for diagnosis and therapy.
- Authors
Jia Zhou; Neale, Joseph H.; Pomper, Martin G.; Kozikowski, Alan P.
- Abstract
Modulation of N-acetyl-L-aspartyl-L-glutamate peptidase activity with small-molecule inhibitors holds promise for a wide variety of diseases that involve glutamatergic transmission, and has implications for the diagnosis and therapy of cancer. This new class of compounds, of which at least one has entered clinical trials and proven to be well tolerated, has demonstrated efficacy in experimental models of pain, schizophrenia, amyotrophic lateral sclerosis, traumatic brain injury and, when appropriately functionalized, can image prostate cancer. Further investigation of these promising drug candidates will be needed to bring them to the marketplace. The recent publication of the X-ray crystal structure for the enzymatic target of these compounds should facilitate the development of other new agents with enhanced activity that could improve both the diagnosis and treatment of neurological disorders.
- Publication
Nature Reviews Drug Discovery, 2005, Vol 4, Issue 12, p1015
- ISSN
1474-1776
- Publication type
Academic Journal
- DOI
10.1038/nrd1903